Here, we provide evidence that physiologic levels of PDE3B, even in the absence of PDE3A, can be sufficient for heterotetrameric complex formation with SLFN12 to induce velcrin-mediated antineoplastic effects, further demonstrating a potential role for PDE3B in velcrin sensitivity in leukemia. This evidence concerns the gene PDE3B and leukemia.